In vitro products for drug discovery, adme-tox and transporter research
ReadyCell, Easing your Screening
The leading manufacturer of ready-to-use cell-based plates
Got a minute?
ReadyCell values your input! Take a quick survey and let us know your opinions on our services. Start the survey now!
New Insights into drug formulation with ready-to-use Caco-2 cells
In a recent study published in the Future Pharmacology Journal, researchers from prestigious French companies examined the impact of four polyols on the permeability of seven active pharmaceutical ingredients (APIs).
Happy Holidays and a Prosperous New Year!
To convey our spirit, we share a Christmas card, proudly supported by ASHOFI, dedicated to aiding individuals affected by fibromyalgia.
3DLIVER: Celebrating one year of progress in the project for advanced drug toxicity testing and discovery
The main aim of the 3DLIVER project is the generation of innovative human liver-derived 3D in vitro models as innovative ready-to-use kits for drug testing models, using human liver cells and extracellular matrix (ECM), to generate more reliable in vitro drug testing devices.
A new study that uses CacoReady reveals a potent inhibitor for prostate cancer
Evaluating in vitro permeability with CacoReady plates was central to the study design. By quantifying the permeability of the synthesized compounds within Caco-2 cells, researchers could identify and select which compounds were best in terms of cellular adsorption.
ReadyCell at the XV Spanish Drug Discovery Network Meeting in PRBB
ReadyCell is pleased to participate in the XV meeting of the Spanish Drug Discovery Network (SDDN) at the Parc de Recerca Biomèdica de Barcelona (PRBB) on November 20th and 21st, 2023.
Japanese distributor OYC meets with ReadyCell in Barcelona
The meeting focused on exploring the current market dynamics and emerging trends in the field of cell culture technology and drug discovery. Both companies, ReadyCell and OYC, are committed to providing their customers with top-tier products and services.